Method for treating amyotrophic lateral sclerosis with a polynucleotide encoding two or more isoforms of hepatocyte growth factor
The present invention relates to a composition for preventing or treating amyotrophic lateral sclerosis, the composition containing, as an active ingredient, two or more isoforms of a hepatocyte growth factor (HGF) or a polynucleotide encoding the isoforms. The composition of the present invention is used to effectively prevent or treat amyotrophic lateral sclerosis.
1. A method for treating amyotrophic lateral sclerosis, the method comprising administering, to a human patient with amyotrophic lateral sclerosis, a composition containing, as an active ingredient, a polynucleotide encoding two or more isoforms of hepatocyte growth factor (HGF), wherein:
the two or more isoforms of HGF comprise a full-length HGF (flHGF) and a deleted variant HGF (dHGF),
the full-length HGF (flHGF) comprises an amino acid sequence of SEQ ID NO:1, and the deleted variant HGF (dHGF) comprises the amino acid sequence of SEQ ID NO: 2.
2. The method of claim 1 , wherein the polynucleotide is naked DNA, or is contained in a gene delivery system.
3. The method of claim 2 , wherein the gene delivery system is a vector.
4. The method of claim 3 , wherein the vector is a plasmid.
5. The method of claim 4 , wherein the vector is pCK.
6. The method of claim 1 , wherein the polynucleotide includes a sequence corresponding to exon 1 to exon 18 of a human HGF gene, and intron 4 of a human HGF gene or a fragment thereof as a sequence additionally inserted between exon 4 and exon 5.
7. The method of claim 6 , wherein the polynucleotide includes a nucleotide sequence selected from the group consisting of SEQ ID NO: 3 to SEQ ID NO: 10.
8. The method of claim 7 , wherein the polynucleotide includes a nucleotide sequence of SEQ ID NO: 9.
9. The method of claim 1 , wherein the polynucleotide is administered at a dose of 1 μg to 2500 mg.
10. A method for treating amyotrophic lateral sclerosis comprising the step of administering, to a human patient with amyotrophic lateral sclerosis, a polynucleotide, wherein the polynucleotide comprises:
(a) a first cDNA which has the same sequence as exons 1-4 of a human HGF gene wherein said exons 1-4 are arranged in sequential order without an intron therebetween, or degenerates thereof which do not alter the amino acid sequence encoded by said first cDNA,
(b) a polynucleotide that has the same sequence as intron 4 of the human HGF gene or a fragment thereof, and
(c) a second cDNA which has the same sequence as exons 5-18 of the human HGF gene wherein said exons 5-18 are arranged in sequential order without an intron therebetween, or degenerates thereof which do not alter the amino acid sequence encoded by said second cDNA;
wherein (b) is located between (a) and (c); and the polynucleotide simultaneously encodes two heterotypes of human HGF.
11. A method for treating amyotrophic lateral sclerosis comprising the step of: intramuscular administration of pCK-HGFX7 to a human patient with amyotrophic lateral sclerosis.